NAMS MENOPAUSE CERTIFICATION
EXAM PRACTICE QUESTIONS AND
ANSWERS
1. Which of the following biomarkers is considered the most reliable indicator of the late
menopausal transition according to the STRAW+10 criteria?
A. Marked variability in cycle length with at least two skipped cycles and an interval of
amenorrhea of 60 days or more
B. High serum Progesterone during the follicular phase
C. A sustained decrease in Thyroid Stimulating Hormone (TSH) levels
D. Consistently low Follicle-Stimulating Hormone (FSH) levels below 10 IU/L
Answer: A
Conceptual Explanation: According to the STRAW+10 staging system, the late
menopausal transition (Stage -1) is characterized by an interval of amenorrhea of 60 days
or more, reflecting increased frequency of non-ovulatory cycles.
,2. A 52-year-old woman with an intact uterus presents with moderate-to-severe hot flashes.
Which hormone therapy (HT) regimen is appropriate to prevent endometrial hyperplasia?
A. Estrogen-only therapy (ET) delivered via a transdermal patch
B. Intermittent high-dose testosterone therapy
C. Low-dose vaginal estradiol cream
D. Combined estrogen-progestogen therapy (EPT)
Answer: D
Conceptual Explanation: Women with an intact uterus who use systemic estrogen must
also take a progestogen to protect the endometrium from hyperplasia and the increased
risk of endometrial cancer.
3. The ‘Timing Hypothesis’ suggests that hormone therapy (HT) has which effect on
cardiovascular disease?
A. HT started close to the onset of menopause (under age 60 or within 10 years of onset)
may reduce cardiovascular risk
B. HT increases the risk of coronary heart disease regardless of when it is started
C. HT is only beneficial for women who are at least 20 years post-menopause
D. HT has no effect on the progression of atherosclerosis in any age group
Answer: A
, Conceptual Explanation: The Timing Hypothesis suggests that HT may have a
cardioprotective effect when initiated near the time of menopause, while starting it later in
life may increase risks due to advanced atherosclerosis.
4. Which FDA-approved non-hormonal medication is specifically indicated for the treatment
of moderate-to-severe vasomotor symptoms (VMS)?
A. Fluoxetine 20mg
B. Paroxetine mesylate 7.5mg
C. Gabapentin 300mg
D. Clonidine 0.1mg
Answer: B
Conceptual Explanation: Paroxetine mesylate 7.5mg is the first FDA-approved non-
hormonal treatment specifically for vasomotor symptoms associated with menopause.
Other SSRIs and Gabapentin are used off-label.
5. What is the primary mechanism of action for Ospemifene in treating Genitourinary
Syndrome of Menopause (GSM)?
A. It acts as a pure estrogen antagonist in all tissues
B. It is a Selective Estrogen Receptor Modulator (SERM) with agonistic effects on the
vaginal epithelium
C. It increases systemic progesterone levels to thicken the vaginal wall
EXAM PRACTICE QUESTIONS AND
ANSWERS
1. Which of the following biomarkers is considered the most reliable indicator of the late
menopausal transition according to the STRAW+10 criteria?
A. Marked variability in cycle length with at least two skipped cycles and an interval of
amenorrhea of 60 days or more
B. High serum Progesterone during the follicular phase
C. A sustained decrease in Thyroid Stimulating Hormone (TSH) levels
D. Consistently low Follicle-Stimulating Hormone (FSH) levels below 10 IU/L
Answer: A
Conceptual Explanation: According to the STRAW+10 staging system, the late
menopausal transition (Stage -1) is characterized by an interval of amenorrhea of 60 days
or more, reflecting increased frequency of non-ovulatory cycles.
,2. A 52-year-old woman with an intact uterus presents with moderate-to-severe hot flashes.
Which hormone therapy (HT) regimen is appropriate to prevent endometrial hyperplasia?
A. Estrogen-only therapy (ET) delivered via a transdermal patch
B. Intermittent high-dose testosterone therapy
C. Low-dose vaginal estradiol cream
D. Combined estrogen-progestogen therapy (EPT)
Answer: D
Conceptual Explanation: Women with an intact uterus who use systemic estrogen must
also take a progestogen to protect the endometrium from hyperplasia and the increased
risk of endometrial cancer.
3. The ‘Timing Hypothesis’ suggests that hormone therapy (HT) has which effect on
cardiovascular disease?
A. HT started close to the onset of menopause (under age 60 or within 10 years of onset)
may reduce cardiovascular risk
B. HT increases the risk of coronary heart disease regardless of when it is started
C. HT is only beneficial for women who are at least 20 years post-menopause
D. HT has no effect on the progression of atherosclerosis in any age group
Answer: A
, Conceptual Explanation: The Timing Hypothesis suggests that HT may have a
cardioprotective effect when initiated near the time of menopause, while starting it later in
life may increase risks due to advanced atherosclerosis.
4. Which FDA-approved non-hormonal medication is specifically indicated for the treatment
of moderate-to-severe vasomotor symptoms (VMS)?
A. Fluoxetine 20mg
B. Paroxetine mesylate 7.5mg
C. Gabapentin 300mg
D. Clonidine 0.1mg
Answer: B
Conceptual Explanation: Paroxetine mesylate 7.5mg is the first FDA-approved non-
hormonal treatment specifically for vasomotor symptoms associated with menopause.
Other SSRIs and Gabapentin are used off-label.
5. What is the primary mechanism of action for Ospemifene in treating Genitourinary
Syndrome of Menopause (GSM)?
A. It acts as a pure estrogen antagonist in all tissues
B. It is a Selective Estrogen Receptor Modulator (SERM) with agonistic effects on the
vaginal epithelium
C. It increases systemic progesterone levels to thicken the vaginal wall
